Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Hold rating on Akoya Biosciences (AKYA – Research Report). The associated price target remains the same with $1.80.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Kyle Mikson CFA has given his Hold rating due to a combination of factors impacting Akoya Biosciences’ financial performance and future prospects. The company’s first-quarter results for 2025 fell short of both the analyst’s estimates and the consensus, with a notable year-over-year revenue decline of approximately 10%. This shortfall was attributed to macroeconomic challenges, including capital purchasing constraints, which affected the company’s sales performance. Additionally, the gross margin decreased significantly compared to previous quarters, and operating expenses exceeded expectations, contributing to a less favorable financial outlook.
Kyle Mikson also considered the broader industry challenges and uncertainties, such as potential impacts from NIH funding on Akoya’s U.S. academic research business and uncertainties in the biopharma market. These factors, along with tariffs, are expected to pose challenges to Akoya’s financial results in the near term. Furthermore, while the merger with Quanterix is anticipated to complete by mid-2025, the immediate benefits of this transaction may not be realized quickly, and the share price is likely to remain subdued near the implied deal price. Given these considerations, the Hold rating reflects a cautious stance on the stock’s potential for significant near-term appreciation.
AKYA’s price has also changed dramatically for the past six months – from $3.190 to $1.160, which is a -63.64% drop .